Gabapentin Capsule
Product Images NDC 63187-810

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 63187-810). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

63187-810 (Gabapentin 300mg Cap)

Label for Gabapentin 300 mg capsules by Proficient Rx LP. The label indicates a package containing 15 capsules. It states each capsule contains Gabapentin USP 300 mg and describes the capsules as yellow hard gelatin with "215" imprinted in blue ink. Manufactured by Alkem Laboratories Ltd. in Mumbai, India, with storage instructions at 20°-25°C (68°-77°F).*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A formula text panel showing the calculation for creatinine clearance (CLCr), which includes patient age, weight, serum creatinine levels, and a factor adjustment for female patients. This panel provides mathematical information related to drug pharmacokinetics or dosing considerations.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph depicting mean pain scores over weeks for placebo and Gabapentin 3600 mg/day. The x-axis shows weeks from baseline to 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, with Gabapentin scores decreasing over time compared to placebo.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph showing mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 10.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data for Study 1 and Study 2. The vertical axis represents percentage responders from 0% to 100%. Study 1 compares PBO (12%) and GBP 3600 (29%). Study 2 compares PBO (14%), GBP 1800 (32%), and GBP 2400 (34%). Statistical significance is indicated with asterisks for some bars.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A chart depicting the percent difference on the vertical axis and daily dose in mg on the horizontal axis for Gabapentin. It shows data points from three studies labeled 'STUDY a', 'STUDY b', and 'STUDY c' with differences increasing as daily dose increases from 600 mg to 1800 mg.*

FDA Label Image

Gabapentin Structure (Gabapentin Struc)

Chemical structure of gabapentin, showing a cyclohexane ring attached to an amino group (CH2NH2) and an acetic acid group (CH2CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.